Condition
Retrolisthesis
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Unknown2
Terminated1
Completed1
Withdrawn1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04416321Not ApplicableCompleted
A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced.
NCT03896347Withdrawn
A Study Evaluating 3-Level OLIF Spine Fusion
NCT05610397Unknown
Retrospective Study With Patients Treated With STALIF® C or M and Ti or FLX Implants for 1 and 2 Levels
NCT02704689Not ApplicableTerminated
AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY
NCT02805985Not ApplicableUnknown
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
Showing all 5 trials